Swedish Orphan starts European Phase III trial of pre-term infant growth drug
This article was originally published in Scrip
Executive Summary
Swedish Orphan Biovitrum has enrolled the first patient in a Phase III trial investigating its treatment for improving growth in preterm infants, Kiobrina (recombinant human bile-salt stimulated lipase; rhBSSL).